GENELUX Corp
GENELUX Corp is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) on December 15, 2026. There are 2 upcoming events on record.
Cash runway is approximately 9.3 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| December 15, 2026 | Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) | Trial Milestone | Phase 3 |
| February 15, 2027 | Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer | Trial Milestone | Phase 2 |
Track GNLX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open GNLX in the tracker| Date | Event | Type | Phase |
|---|---|---|---|
| March 19, 2026 | 8-K filed: Material agreement | Corporate | — |
| February 2, 2026 | 8-K filed: Reg FD disclosure | Filing | — |
| January 8, 2026 | 8-K filed: Other event | Filing | — |
| January 5, 2026 | 8-K filed: Reg FD disclosure, Other event | Filing | — |
| January 2, 2026 | 8-K filed: Leadership change | Corporate | — |
| September 3, 2025 | 8-K filed: Leadership change | Corporate | — |
| December 31, 2021 | Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer | Trial Milestone | Phase 1/Phase 2 |
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.